Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Chronic ocular tolerability and pharmacodynamics of the RTC-1119 intracameral implant in normotensive beagle dogs
Author Affiliations & Notes
  • Kyle Battiston
    Ripple Therapeutics, Ontario, Canada
  • Shadi Taghavi
    Ripple Therapeutics, Ontario, Canada
  • Hans Fischer
    Ripple Therapeutics, Ontario, Canada
  • Matthew Statham
    Ripple Therapeutics, Ontario, Canada
  • Jonathan Day
    Ripple Therapeutics, Ontario, Canada
  • Emily Baldwin
    Ripple Therapeutics, Ontario, Canada
  • Adam Daley
    Ripple Therapeutics, Ontario, Canada
  • Ian Parrag
    Ripple Therapeutics, Ontario, Canada
  • Wendy Naimark
    Ripple Therapeutics, Ontario, Canada
  • Footnotes
    Commercial Relationships   Kyle Battiston Ripple Therapeutics, Code E (Employment), Ripple Therapeutics, Code P (Patent); Shadi Taghavi Ripple Therapeutics, Code E (Employment); Hans Fischer Ripple Therapeutics, Code E (Employment); Matthew Statham Ripple Therapeutics, Code E (Employment), Ripple Therapeutics, Code P (Patent); Jonathan Day Ripple Therapeutics, Code E (Employment), Ripple Therapeutics, Code P (Patent); Emily Baldwin Ripple Therapeutics, Code E (Employment); Adam Daley Ripple Therapeutics, Code E (Employment); Ian Parrag Ripple Therapeutics, Code E (Employment), Ripple Therapeutics, Code O (Owner), Ripple Therapeutics, Code P (Patent); Wendy Naimark Ripple Therapeutics, Code E (Employment), Ripple Therapeutics, Code O (Owner), Ripple Therapeutics, Code P (Patent)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3971. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kyle Battiston, Shadi Taghavi, Hans Fischer, Matthew Statham, Jonathan Day, Emily Baldwin, Adam Daley, Ian Parrag, Wendy Naimark; Chronic ocular tolerability and pharmacodynamics of the RTC-1119 intracameral implant in normotensive beagle dogs. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3971.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Prostaglandin eye drops, such as latanoprost, are first-line therapy for patients in the management of ocular hypertension and glaucoma. However, poor compliance with topical dosing regimens can lead to disease progression. There is a need for sustained release therapeutics for intraocular pressure (IOP) management to improve patient quality of care. The RTC-1119 IC Implant is a sustained release implant comprised entirely of a latanoprost acid prodrug, RTC-1119. The RTC-1119 IC Implant undergoes surface erosion to provide controlled, sustained release of latanoprost acid, while the lack of polymers and excipients ensures no residue is left behind following drug release. The purpose of this work was to assess the IOP-lowering ability and ocular tolerability of two doses of the RTC-1119 IC Implant in normotensive beagle dogs.

Methods : RTC-1119 IC Implants were prepared by melt extrusion followed by cutting to desired length to obtain low dose (30 µg latanoprost acid) and high dose (140 µg latanoprost acid) RTC-1119 IC Implants. Normotensive male beagle dogs received a sham intracameral procedure or bilateral administration of low dose or high dose RTC-1119 IC Implants (N=3 dogs/N=6 eyes per group). Pharmacodynamics was assessed by tonometry and pupillometry. Ocular tolerability was assessed by anterior optical coherence tomography, pachymetry, ocular exams, gonioscopy, and histopathology.

Results : Following intracameral administration, both low and high dose RTC-1119 IC Implants demonstrated IOP-lowering and pupil constriction consistent with anticipated pharmacological effects of prostaglandin analogs in beagle dogs for the duration of the study (~18 mo) (Figure 1). RTC-1119 IC Implants were well tolerated, with no significant findings on ocular exams and no difference in corneal thickness compared to sham-treated eyes. Ocular histopathology assessment indicated no test article-related findings.

Conclusions : Results support the further development of RTC-1119 as a well-tolerated intracameral implant capable of providing IOP-lowering for >12 mo following a single implant administration in patients with ocular hypertension and open angle glaucoma.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Figure 1 Change in (A) intraocular pressure and (B) pupil diameter following RTC-1119 IC Implant administration. N=6 eyes/group. Data are the mean +/- S.E.

Figure 1 Change in (A) intraocular pressure and (B) pupil diameter following RTC-1119 IC Implant administration. N=6 eyes/group. Data are the mean +/- S.E.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×